Multiple indications for everolimus after liver transplantation in current clinical practice

Table 7 Adverse events, causes of discontinuation and mortality n (%)

	Patients receiving everolimus (n = 74)
Adverse events	27 (36.5)
Dyslipidemia	27 (36.5)
Infections	9 (12.2)
Mucositis	3 (4.1)
Diarrhoea	1 (1.4)
Proteinuria	1 (1.4)
Acute rejections post-conversion	11 (14.9)
Causes of discontinuation	21 (28.4)
Resolution of the cause of conversion	6 ( 8.1)
Non-responding rejection and retransplantation	6 ( 8.1)
Drug-related adverse events	5 ( 6.7)
Intercurrent surgery	4 ( 5.5 )
Causes of mortality	25 (33)
HCC recurrence during follow-up	10
De novo tumour	4
HCV recurrence	4
Chronic rejection	4
Sepsis	1
Graft-vs-host disease	1
Other causes	1

HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus.